Business Wire

SECURE-CODE-WARRIOR

2.6.2022 14:02:13 CEST | Business Wire | Press release

Share
Secure Code Warrior and Okta Collaborate to Create New Solution to Secure Developer Workflows

Secure Code Warrior , the global, developer-driven security leader, today announced an exciting addition to the Okta Integration Network. Okta , the leading independent provider of identity, and Secure Code Warrior collaborated to deliver a new solution - the Secure Code Warrior (SCW) Connector for Okta Workflows, which enables organizations and developers to write secure code from the start of the software development lifecycle (SDLC).

Applying a security-first mindset, organizations can design an identity workflow that protects builds from the beginning of the life cycle, giving organizations the flexibility to only provide GitHub repo access to security proficient developers. This helps organizations promote a security first culture while the SCW Learning Platform enables developers to meet these standards and requirements. Organizations have implemented this solution across their application, security and engineering teams to provide this additional layer of security.

Preventing insecure code and ensuring better access control during software development remains a significant need for industries across all verticals. Meanwhile, developers recognize the importance of delivering secure software applications but face competing priorities. According to SCW’s recently released “The State of Developer-Driven Security Survey, 2022” , 67% knowingly left vulnerabilities and exploits in their code, with a lack of time and a cohesive approach cited as the two main barriers to the adoption of secure coding practices.

“This new solution will help organizations reduce the risk of developers committing insecure code by ensuring that employees are up to date on the latest vulnerabilities and secure coding techniques. Through our work together with Okta on a security proficiency check, AppSec Managers can be confident that the team is committing secure code without moving developers out of their workflow. Now, leaders can focus on broad strategic efforts to improve the organization’s security posture without sacrificing quality or time.” said Pieter Danhieux, Co-founder and CEO, Secure Code Warrior.

“Okta Workflows provides a no-code, low-code approach to automating identity-centric processes at scale. As an early adopter of Workflows Connector Builder, we are excited to have the new Secure Code Warrior connector in the Okta Integration Network, which goes beyond SSO and provisioning to support advanced integration flows. Developers can be confident that their secure code knowledge is up to date and relevant to the code they are committing” said David Shackelford, Senior Director, Okta.

The Secure Code Warrior Connector for Okta Workflows utilizes key components of both companies’ technology platforms to benefit organizations and developers alike:

  • Pre-configured actions enable developer teams to quickly build the desired workflows in a no-code/low code environment, without the hassle of getting into the complexities of API calls.
  • Once the workflow is ready, it will run automatically and can be customized for frequency.
  • Secure Code Warrior’s Learning Platform provides information on the developers’ assessment score and course completion status, giving teams the insights to determine their security skills when writing code.
  • Organizations have the flexibility to only allow GitHub repo access to security proficient developers

Creating and automating secure developer workflows is now easier than ever thanks to this new industry solution from Secure Code Warrior and Okta. The Secure Code Warrior Connector for Okta Workflows is available at https://help.okta.com/wf/en-us/Content/Topics/Workflows/connector-reference/securecodewarrior/securecodewarrior.htm .

To learn more, visit www.securecodewarrior.com/blog/scw-connector-for-okta-workflows .

About Secure Code Warrior
Secure Code Warrior builds a culture of security-driven developers by giving them the skills to code securely. Our flagship Learning Platform delivers relevant skills-based pathways, hands-on missions, and contextual tools for developers to rapidly learn, build, and apply their skills to write secure code at speed. Established in 2015, Secure Code Warrior has become a critical component for over 450 enterprises including leading financial services, retail, and global technology companies across the world. Visit: www.securecodewarrior.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye